Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biogen -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (1005)	6/9/1999 11:09:00 PM
From: P.M.Freedman	Read Replies (3) \| Respond to of 1686

Let's do a bit math. Assuming Biogen's claim came true in three years, that is 100,000 MS-patients take Avonex, it will create $1.2 billion per year from final user cost. It will be quarterly 300 million only. The sales of Biogen in last quarter were 131 million which were mainly from Avonex, almost equal to the half year final user cost in three years later. If we count the real $$$ that to go to Biogen, we have to modify the numbers significantly. What do you think? We won't not see more new drugs in Biogen's pipeline that are going to the markets in next two years. So, Avonex will be at least being the money maker for Biogen. Does anyone is expecting 1 million MS patients in the near future will be taking Avonex?